RxDoctor Payments Data

Eric Braun, MD

Family Medicine · Waco, TXNPI 1831501634

Payments from drug & device makers

$1,861in general payments, 2019–2025

Across 117 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$340
  • Pfizer$234
  • GSK$199
  • AbbVie$175
  • AstraZeneca$168
  • Amgen$161
  • plus $585 from 18 others

What the payments were for

  • Food & beverage$1,855100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,861 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$99,234
Medicare patients
181
Services billed
1,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide304$354,411
OzempicSemaglutide113$120,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$59,354
EliquisApixaban43$38,572
JardianceEmpagliflozin25$33,811
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$20,318
MyrbetriqMirabegron23$18,450
Nurtec OdtRimegepant Sulfate14$15,452
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,031
Aimovig AutoinjectorErenumab-Aooe13$8,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$6,140
Gabapentin240$3,816
Incruse ElliptaUmeclidinium Bromide11$3,695
Albuterol Sulfate HfaAlbuterol Sulfate111$3,642
Atorvastatin Calcium516$3,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$13$354,411304 claims
Novo NordiskOzempic$340$120,536113 claims
GSKTrelegy Ellipta, Incruse Ellipta$199$63,04989 claims
PfizerEliquis, Nurtec Odt$234$54,02457 claims
Boehringer IngelheimJardiance$25$33,81125 claims
AstraZenecaBreztri Aerosphere$168$20,31824 claims
Astellas Pharma US IncMyrbetriq$56$18,45023 claims
AbbVieSynthroid$175$1,96427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →